EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies

Maria V Bourganou iD, Maria Eleni Chondrogianni, Ioannis Kyrou iD, Christina-Maria Flessa iD, Antonios Chatzigeorgiou iD, Evangelos Oikonomou iD, Vaia Lambadiari, Harpal S Randeva, Eva Kassi iD

International Journal of Molecular Sciences · 13.02.2025 · 26 (4) · 1589

DOI: 10.3390/ijms26041589 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.02.2025. Verfasst von Maria V Bourganou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolomics, Genomics. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 252 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is the most prevalent liver disorder globally, linked to obesity, type 2 diabetes, and cardiovascular risk. Understanding its potential progression from simple steatosis to cirrhosis and hepatocellular carcinoma (HCC) is crucial for patient management and treatment strategies. The disease’s complexity requires innovative approaches for early detection and personalized care. Omics technologies—such as genomics, transcriptomics, proteomics, metabolomics, and exposomics—are revolutionizing the study of MASLD. These high-throughput techniques allow for a deeper exploration of the molecular mechanisms driving disease progression. Genomics can identify genetic predispositions, whilst transcriptomics and proteomics reveal changes in gene expression and protein profiles during disease evolution. Metabolomics offers insights into the metabolic alterations associated with MASLD, while exposomics links environmental exposures to MASLD progression and pathology. By integrating data from various omics platforms, researchers can map out the intricate biochemical pathways involved in liver disease progression. This review discusses the roles of omics technologies in enhancing the understanding of disease progression and highlights potential diagnostic and therapeutic targets within the MASLD spectrum, emphasizing the need for non-invasive tools in disease staging and treatment development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseMetabolomicsGenomicsHumansProteomicsAnimalsDisease ProgressionTranscriptomeCarcinoma, Hepatocellular

Stichwörter der Autor:innen

biomarkersexposomicsgenomicsmetabolic dysfunction-associated fatty liver disease (MAFLD)metabolic dysfunction-associated steatotic liver disease (MASLD)metabolomicsnon-alcoholic fatty liver disease (NAFLD)omics technologiesproteomicstranscriptomics

Autor:innen und Institutionen

  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Endocrine Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, School of Food and Nutritional Sciences, Agricultural University of Athens, 11855 Athens, Greece.
  • Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
  • Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
  • Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.

ORCID-Profile: Maria V Bourganou, Ioannis Kyrou, Christina-Maria Flessa, Antonios Chatzigeorgiou, Evangelos Oikonomou, Eva Kassi

Zitieren

APA

Bourganou, M. V., Chondrogianni, M. E., Kyrou, I., Flessa, C. M., Chatzigeorgiou, A., Oikonomou, E., Lambadiari, V., Randeva, H. S., & Kassi, E. (2025). Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies. International Journal of Molecular Sciences, 26(4), 1589. https://doi.org/10.3390/ijms26041589

Vancouver

Bourganou MV, Chondrogianni ME, Kyrou I, Flessa CM, Chatzigeorgiou A, Oikonomou E, et al. Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies. International Journal of Molecular Sciences. 2025;26(4):1589. doi:10.3390/ijms26041589

BibTeX
@article{Bourganou2025,
  author = {Bourganou, Maria V and Chondrogianni, Maria Eleni and Kyrou, Ioannis and Flessa, Christina-Maria and Chatzigeorgiou, Antonios and Oikonomou, Evangelos and Lambadiari, Vaia and Randeva, Harpal S and Kassi, Eva},
  title = {Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {4},
  pages = {1589},
  doi = {10.3390/ijms26041589}
}
Kostenlos starten →